"The findings, published Friday in the Journal of the American College of Cardiology, provide a deeper analysis of Novo's largest Wegovy trial, called Select."
"While insurers and lawmakers assail prices for weight-loss treatments, Novo and Eli Lilly & Co. strive to show their costly drugs offer broad benefits that merit coverage from insurers."
"We do not know if this relates to the reduced lung capacity of individuals with obesity or other pathways such as reduced inflammation."
"The latest results underscore the drug's far-reaching effects on metabolism and inflammation, important factors in the body's response to infection and other types of disease."
Collection
[
|
...
]